Viridian Therapeutics (VRDN)
(Real Time Quote from BATS)
$20.79 USD
-0.33 (-1.56%)
Updated Sep 24, 2024 09:58 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Viridian Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 3 | 1 | 4 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 2 | 3 | 1 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 255 | 136 | 83 | 111 | 46 |
Income After Depreciation & Amortization | -254 | -134 | -80 | -110 | -42 |
Non-Operating Income | 19 | 5 | 0 | 0 | 1 |
Interest Expense | 2 | 0 | 0 | 1 | 1 |
Pretax Income | -238 | -130 | -79 | -111 | -42 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -238 | -130 | -79 | -111 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -238 | -130 | -79 | -111 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -265 | -134 | -79 | -110 | -42 |
Depreciation & Amortization (Cash Flow) | -11 | 0 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -254 | -134 | -80 | -110 | -42 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.76 | 32.09 | 11.92 | 3.56 | 2.09 |
Diluted EPS Before Non-Recurring Items | -5.31 | -4.05 | -6.68 | -11.49 | -20.09 |
Diluted Net EPS (GAAP) | -5.31 | -4.05 | -6.66 | -31.13 | -20.09 |
Fiscal Year end for Viridian Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
SG&A, R&D, and Dept/Amort Expenses | 72.26 | 55.97 | 71.55 | 51.30 | 59.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | -72.19 | -55.90 | -71.48 | -51.23 | -59.27 |
Non-Operating Income | 7.79 | 7.94 | 5.53 | 4.16 | 4.38 |
Interest Expense | 0.60 | 0.59 | 0.92 | 0.60 | 0.17 |
Pretax Income | -64.99 | -48.54 | -66.86 | -47.66 | -55.06 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -64.99 | -48.54 | -66.86 | -47.66 | -55.06 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -64.99 | -48.54 | -66.86 | -47.66 | -55.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 63.86 | 61.10 | 49.68 | 43.66 | 43.25 |
Diluted EPS Before Non-Recurring Items | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 |
Diluted Net EPS (GAAP) | -1.02 | -0.79 | -1.34 | -1.09 | -1.27 |